Dissolution tests for extended-release products

Oral Drug Absorption: Prediction and Assessment

Volumn , Issue , 2000, Pages 183-195

  Stevert, Barbara ^a   Siewert, Martin ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007442480     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (21)

1. Wagner JG, Nelson E. Per cent absorbed time plots derived from biuod level and/or urinary excretion data. J Pharm Sci 1963; 52: 610-611.
2. Levy G. Effect of dosage form on drug absorption-a frequent variable in clinical pharmacology. Arch Int Pharmacodyn 1964; 152: 59-68.
3. Loo JCK, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968; 57: 918-928.
4. U.S. Pharmacopeia (USP). Dissolution, USP XVIII, 1970:934-935
5. Joint Report of the Section for Control Laboratories and the Section of Industrial Pharmacists of FIP. Guidelines for dissolution testing of solid oral products. Phann Ind 1981; 43: 334-343.
6. Langenbucher F. Numerical convotution/decon volution as a tool for correlating in vitro with in vivo drug availability. Pharm Ind 1982; 44: 1166-1172.
7. Brockmeier D, Voegele D, van Hattingberg HM. In vitro-in vivo correlation, a time scaling problem? Arzneimittelforsehung 1983; 33:598-601
8. USP Subcommittee on Biopharmaceutics. In vitro/in vivo correlation for extended release oral dosage forms. Pharm Forum 1988; 14: 4160-4161.
9. Karim A. importance of assessing “food effects” in evaluating controlleci-release formulations. In: Yacobi A, Halperin-Walega E, eds. Oral Sustained Release Formulations; Design and Evaluations. New York: Pergamon Press, 1988.
10. Steinijans VE, Dietrich R, Trautmann H, SauterR, Benedikt G. A novel approach to the specification of in vitro dissolution boundaries based on regulatory requirements for once-daily administration. Arzneimittelforsehung 1988; 38: 1203-1209.
11. Nicklasson M, Langenbucher F, Description and evaluation of the flow cell dissolution apparatus as an alternative test method for drug release. Pharm Forum 1990; 16:532-540.
12. EEC Note for Guidance, Quality of prolonged release oral solid dosage forms, III/3172/91-EN 1991.
13. FDA Interim Guidance. Immediate Release Solid Oral Dosage Forms-Pre-and Post-Approval Changes. 1994.
14. Bio-International Conference, Munich, Germany, 1994.
15. USP. (1088) In vitro in vivo evaluation of dosage forms. USP 23, 1995.
16. FIP Guidelines for Dissolution Testing of Solid Oral Products. Pharm Ind 1997; 59:760-766.
17. Guidance for Industry SUP AC-MR: Modified-Release Solid Oral Dosage Forms Scale-Up and Post Approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bio equivalence Documentation. 1997.
18. FDA Guidance for Industry. Extended Release Solid Oral Dosage Forms. Development, Evaluation and Application of In Vitro/In Vivo Correlations. 1997.
19. European Pharmacopoeia
20. USP 23. 1995.
21. Maturu PU, Prasad VK, Worsely WN, Shiu GU, Skelly JP. Influence of a high fat breakfast on the bioavailability of theophylline controlled release formula-lions: an in vitro demonstration of an in vivo observation. J Pharm Sci 1986; 75: 1205-1206.